Frank Chan - 16 May 2025 Form 4 Insider Report for HAEMONETICS CORP (HAE)

Role
EVP, Chief Operating Officer
Signature
/s/ Thomas V. Powers, attorney-in-fact for Mr. Chan
Issuer symbol
HAE
Transactions as of
16 May 2025
Transactions value $
$0
Form type
4
Filing time
20 May 2025, 17:24:29 UTC
Previous filing
09 Apr 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Chan Frank EVP, Chief Operating Officer 125 SUMMER STREET, BOSTON /s/ Thomas V. Powers, attorney-in-fact for Mr. Chan 20 May 2025 0002061743

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HAE Common Stock Award +5.69K 5.69K 16 May 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HAE Non-qualified Stock Option (Right to Buy) Award $0 +12.3K $0.00 12.3K 16 May 2025 Common Stock 12.3K $70.31 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F2 Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F3 Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.